Shahab Asgharzadeh

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2638833/publications.pdf

Version: 2024-02-01

84 papers	7,110 citations	76326 40 h-index	76900 74 g-index
85 all docs	85 docs citations	85 times ranked	9784 citing authors

#	Article	IF	Citations
1	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	21.4	990
2	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
3	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
4	Exosome-Mediated Transfer of microRNAs Within the Tumor Microenvironment and Neuroblastoma Resistance to Chemotherapy. Journal of the National Cancer Institute, 2015, 107, .	6.3	298
5	VÎ±24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. Journal of Clinical Investigation, 2009, 119, 1524-1536.	8.2	287
6	Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma. New England Journal of Medicine, 2008, 358, 2585-2593.	27.0	271
7	Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nature Genetics, 2009, 41, 718-723.	21.4	266
8	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. Journal of Clinical Oncology, 2012, 30, 3525-3532.	1.6	236
9	Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2. Journal of Experimental Medicine, 2004, 199, 1213-1221.	8.5	215
10	Prognostic Significance of Gene Expression Profiles of Metastatic Neuroblastomas Lacking MYCN Gene Amplification. Journal of the National Cancer Institute, 2006, 98, 1193-1203.	6.3	212
11	NF1 Is a Tumor Suppressor in Neuroblastoma that Determines Retinoic Acid Response and Disease Outcome. Cell, 2010, 142, 218-229.	28.9	190
12	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
13	Intensive induction chemotherapy followed by high dose chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatric Blood and Cancer, 2008, 51, 235-240.	1.5	149
14	ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome. Cancer Cell, 2009, 15, 328-340.	16.8	132
15	CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research, 2015, 75, 3155-3166.	0.9	132
16	Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells. Cancer Research, 2017, 77, 5142-5157.	0.9	130
17	Prognostic Impact of Gene Expressionâ€“Based Classification for Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3506-3515.	1.6	129
18	IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. Journal of Clinical Investigation, 2012, 122, 2221-2233.	8.2	126

#	Article	IF	Citations
19	Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatric Blood and Cancer, 2008, 50, 312-318.	1.5	125
20	Cross-Cohort Analysis Identifies a TEAD4â€“MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discovery, 2018, 8, 582-599.	9.4	119
21	Sparse representation and Bayesian detection of genome copy number alterations from microarray data. Bioinformatics, 2008, 24, 309-318.	4.1	113
22	Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatric Blood and Cancer, 2007, 49, 34-40.	1.5	104
23	A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell, 2015, 28, 599-609.	16.8	99
24	TGFÎ²R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells. Clinical Cancer Research, 2017, 23, 804-813.	7.0	98
25	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	1.6	98
26	Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity. Cancer Research, 2012, 72, 2068-2078.	0.9	97
27	Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas. Clinical Cancer Research, 2015, 21, 1457-1465.	7.0	92
28	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. Clinical Cancer Research, 2018, 24, 5673-5684.	7.0	92
29	NK Cellâ€derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells. Journal of Immunotherapy, 2017, 40, 265-276.	2.4	86
30	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature Communications, 2021, 12, 511.	12.8	85
31	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
32	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
33	Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-Oncology, 2016, 18, 126-131.	1.2	69
34	Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFÎ²1. Cancer Immunology, Immunotherapy, 2013, 62, 1637-1648.	4.2	64
35	More than the genes, the tumor microenvironment in neuroblastoma. Cancer Letters, 2016, 380, 304-314.	7.2	64
36	Trends in childhood brain tumor incidence, 1973â€“2009. Journal of Neuro-Oncology, 2013, 115, 153-160.	2.9	62

#	Article	IF	Citations
37	Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells. Clinical Immunology, 2013, 149, 55-64.	3.2	53
38	Pediatric Brain Tumor Cell Lines. Journal of Cellular Biochemistry, 2015, 116, 218-224.	2.6	50
39	An integrated cross-platform prognosis study on neuroblastoma patients. Genomics, 2008, 92, 195-203.	2.9	47
40	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Letters, 2016, 371, 214-224.	7.2	46
41	Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC. Oncotarget, 2017, 8, 91516-91529.	1.8	45
42	Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells. Journal of Immunotherapy, 2013, 36, 319-329.	2.4	42
43	Multiâ€site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system. Cytometry Part B - Clinical Cytometry, 2020, 98, 146-160.	1.5	41
44	Expression of Five Neuroblastoma Genes in Bone Marrow or Blood of Patients with Relapsed/Refractory Neuroblastoma Provides a New Biomarker for Disease and Prognosis. Clinical Cancer Research, 2017, 23, 5374-5383.	7.0	38
45	Joint estimation of copy number variation and reference intensities on multiple DNA arrays using GADA. Bioinformatics, 2009, 25, 1223-1230.	4.1	37
46	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
47	PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. Clinical Cancer Research, 2014, 20, 827-836.	7.0	29
48	Prediction of human functional genetic networks from heterogeneous data using RVM-based ensemble learning. Bioinformatics, 2010, 26, 807-813.	4.1	28
49	Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma. OncoImmunology, 2021, 10, 1838140.	4.6	22
50	Neuroblastoma: Issues in Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, S92-S100.	2.0	20
51	Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma. Genome Research, 2020, 30, 1228-1242.	5.5	20
52	TARGETgene: A Tool for Identification of Potential Therapeutic Targets in Cancer. PLoS ONE, 2012, 7, e43305.	2.5	19
53	Detecting Changes in DNA Copy Number: Reviewing signal processing techniques. IEEE Signal Processing Magazine, 2012, 29, 98-107.	5.6	16
54	Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. Frontiers in Oncology, 2015, 5, 191.	2.8	16

#	Article	IF	Citations
55	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.9	15
56	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	1.2	14
57	Wavelet Footprints and Sparse Bayesian Learning for DNA Copy Number Change Analysis. , 2007, , .		13
58	Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance. Cancer Immunology, Immunotherapy, 2022, 71, 153-164.	4.2	13
59	Enhancing Natural Killer and CD8⁺T Cell-Mediated Anticancer Cytotoxicity and Proliferation of CD8⁺T Cells with HLA-E Monospecific Monoclonal Antibodies. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2019, 38, 38-59.	1.6	12
60	Rare MYC-amplified Neuroblastoma With Large Cell Histology. Pediatric and Developmental Pathology, 2018, 21, 461-466.	1.0	11
61	A genome-wide association study on medulloblastoma. Journal of Neuro-Oncology, 2020, 147, 309-315.	2.9	10
62	MYCN-Dependent Expression of Sulfatase-2 Regulates Neuroblastoma Cell Survival. Cancer Research, 2014, 74, 5999-6009.	0.9	9
63	Copy number variation signature to predict human ancestry. BMC Bioinformatics, 2012, 13, 336.	2.6	8
64	Novel Pathways to Erythropoiesis Induced by Dimerization of Intracellular C-Mpl in Human Hematopoietic Progenitors. Stem Cells, 2012, 30, 697-708.	3.2	8
65	Microarray classification using block diagonal linear discriminant analysis with embedded feature selection. , 2009, , .		7
66	Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Experimental Cell Research, 2015, 334, 78-89.	2.6	7
67	BarTeL, a Genetically Versatile, Bioluminescent and Granule Neuron Precursor-Targeted Mouse Model for Medulloblastoma. PLoS ONE, 2016, 11, e0156907.	2.5	7
68	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. Journal of Neuro-Oncology, 2019, 145, 375-383.	2.9	7
69	Ultra-High Dose Vitamin D in Pediatric Hematopoietic Stem Cell Transplantation: A Nonrandomized Controlled Trial. Transplantation and Cellular Therapy, 2021, 27, 1001.e1-1001.e9.	1.2	6
70	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. PLoS ONE, 2014, 9, e108818.	2.5	6
71	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2022, 40, 10003-10003.	1.6	6
72	Bioinformatics for Copy Number Variation Data. Methods in Molecular Biology, 2011, 719, 235-249.	0.9	4

#	Article	IF	Citations
73	Adaptation of Imaging Mass Cytometry to Explore the Single Cell Alloimmune Landscape of Liver Transplant Rejection. Frontiers in Immunology, 2022, 13, 831103.	4.8	4
74	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
75	Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method. Pharmaceutical Statistics, 2019, 18, 659-670.	1.3	2
76	Phase I study of ¹³¹I-MIBG with dinutuximab for patients with relapsed or refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium.. Journal of Clinical Oncology, 2022, 40, 10038-10038.	1.6	2
77	Bayesian detection of recurrent copy number alterations across multiple array samples. , 2008, , .		1
78	MB-53hTERT EXPRESSION AND REGULATION IN PEDIATRIC MEDULLOBLASTOMA (MB). Neuro-Oncology, 2016, 18, iii109.2-iii109.	1.2	1
79	MB-34 * MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IDENTIFICATION USING NON-INVASIVE MAGNETIC RESONANCE SPECTROSCOPY. Neuro-Oncology, 2015, 17, iii27-iii27.	1.2	0
80	MBCL-49. PROGNOSTIC SIGNIFICANCE OF MOLECULAR SUBGROUPS OF MEDULLOBLASTOMA IN CHILDREN RECEIVING IRRADIATION-SPARING REGIMENS. Neuro-Oncology, 2018, 20, i128-i128.	1.2	0
81	Role of C-C Motif Chemokine Ligand 2 in Metastatic Neuroblastoma. Journal of the American College of Surgeons, 2019, 229, S217.	0.5	0
82	Comparison of Taqman low density array (TLDA) five-gene assay for tumor cells in bone marrow and blood with histologic bone marrow examination and imaging for disease assessment and outcome in patients with recurrent/refractory neuroblastoma (NBL): A new approaches to neuroblastoma therapy (NANT) study.. Journal of Clinical Oncology, 2013, 31, 10039-10039.	1.6	0
83	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients â‰¥18 months with unfavorable histology and without MYCN amplification: A Childrenâ€™s Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10502-10502.	1.6	0
84	Expression of neuroblastomaâ€related genes in bone marrow at end of highâ€risk neuroblastoma therapy. Pediatric Blood and Cancer, 2022, , e29719.	1.5	0